Anti-tumor treatment and healthcare consumption near death in the era of novel treatment options for patients with melanoma brain metastases

Table 2 Number of patients receiving anti-tumor treatment near death

	Overall N = 100 n (%)	BRAF + N = 66 n (%)	BRAF - N = 34 n (%)	P-value X²
Systemic treatment
last 3 months Last month Last week	72 (72%) 34 (34%) 6 (6%)	56 (85%) 28 (42%) 5 (8%)	16 (47%) 6 (18%) 1 (3%)	< 0.001 0.01 0.36
Localized treatment
last 3 months Last month Last week	40 (40%) 14 (14%) 4 (4%)	22 (33%) 9 (14%) 3 (5%)	18 (52%) 5 (15%) 1 (3%)	0.06 0.88 0.58 ^a

ISSN: 1471-2407